Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric B Haura

Showing results (181-190 of 201) with videos related to

Pageof 21
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|September 14, 2020
Managing a Large-Scale Multiomics Project: A Team Science Case Study in ProteogenomicsPaul A Stewart, Eric A Welsh, Bin Fang, et al.
Nature Medicine|September 14, 2023
Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trialByoung Chul Cho, Dong-Wan Kim, Alexander I Spira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 5, 2017
Common <i>TDP1</i> Polymorphisms in Relation to Survival among Small Cell Lung Cancer Patients: A Multicenter Study from the International Lung Cancer ConsortiumPawadee Lohavanichbutr, Lori C Sakoda, Christopher I Amos, et al.
International Journal of Radiation Oncology, Biology, Physics|January 19, 2023
Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung CancerCasey L Liveringhouse, Kujtim Latifi, Amalin G Asous, et al.
JCO Precision Oncology|December 22, 2025
CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (<i>NRG1</i>) FusionsTejas Patil, Jessica J Lin, Parneet K Cheema, et al.
Biorxiv : the Preprint Server for Biology|December 12, 2025
TAp73 mediates anti-tumor immunity through regulation of lipid metabolism in the lung tumor microenvironmentHayley D Ackerman, Vanessa Y Rubio, Andrew J Davis, et al.
Nature Medicine|September 13, 2022
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trialJamie E Chaft, Filiz Oezkan, Mark G Kris, et al.
Nature Cancer|May 9, 2025
Impaired T cell and neoantigen retention in time-serial analysis of metastatic non-small cell lung cancer in patients unresponsive to TIL cell therapyChao Wang, Xiaoqing Yu, Jamie K Teer, et al.
Nature Medicine|August 13, 2021
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trialBenjamin C Creelan, Chao Wang, Jamie K Teer, et al.
JAMA|May 22, 2014
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugsMark G Kris, Bruce E Johnson, Lynne D Berry, et al.
Pageof 21

Showing results (181-190 of 201) with videos related to

Sort By:
Pageof 21
Methods in Molecular Biology (Clifton, N.J.)|September 14, 2020
Managing a Large-Scale Multiomics Project: A Team Science Case Study in ProteogenomicsPaul A Stewart, Eric A Welsh, Bin Fang, et al.
Nature Medicine|September 14, 2023
Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trialByoung Chul Cho, Dong-Wan Kim, Alexander I Spira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 5, 2017
Common <i>TDP1</i> Polymorphisms in Relation to Survival among Small Cell Lung Cancer Patients: A Multicenter Study from the International Lung Cancer ConsortiumPawadee Lohavanichbutr, Lori C Sakoda, Christopher I Amos, et al.
International Journal of Radiation Oncology, Biology, Physics|January 19, 2023
Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung CancerCasey L Liveringhouse, Kujtim Latifi, Amalin G Asous, et al.
JCO Precision Oncology|December 22, 2025
CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (<i>NRG1</i>) FusionsTejas Patil, Jessica J Lin, Parneet K Cheema, et al.
Biorxiv : the Preprint Server for Biology|December 12, 2025
TAp73 mediates anti-tumor immunity through regulation of lipid metabolism in the lung tumor microenvironmentHayley D Ackerman, Vanessa Y Rubio, Andrew J Davis, et al.
Nature Medicine|September 13, 2022
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trialJamie E Chaft, Filiz Oezkan, Mark G Kris, et al.
Nature Cancer|May 9, 2025
Impaired T cell and neoantigen retention in time-serial analysis of metastatic non-small cell lung cancer in patients unresponsive to TIL cell therapyChao Wang, Xiaoqing Yu, Jamie K Teer, et al.
Nature Medicine|August 13, 2021
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trialBenjamin C Creelan, Chao Wang, Jamie K Teer, et al.
JAMA|May 22, 2014
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugsMark G Kris, Bruce E Johnson, Lynne D Berry, et al.
Pageof 21